Le Lézard
Classified in: Science and technology
Subject: PDT

VRComfort Vuetm immersion platform redesigned to utilize standard gaming chairs.


VRComfort Labs, Inc. announced a new VRComfort Vuetm stationary boundary system will be available as an inexpensive and easily installed gaming chair attachment for use with a Meta Quest 2 headset. The original design was more complex, more expensive and could only be purchased as part of a fully integrated platform.

NEWPORT BEACH, Calif., April 29, 2024 /PRNewswire-PRWeb/ -- VRComfort Labs, Inc. stated the previous VRComfort Vuetm design required VRComfort Labs to receive a specific high end gaming chair model, manufactured by only one company. After each chair was received, time consuming and labor-intensive modifications was required to install the VRComfort Vuetm assembly. With the new design, this is no longer required, and an innovative business model will also be implemented.

"VRComfort Labs believes the new business model may be the first to utilize Amazon for a complete system integration application."

The VRComfort Vuetm assembly will be the only platform component sold by VRComfort Labs. Additional platform components including the gaming chair, Quest 2 VR headset, 12 volt 5ah battery, cushioned facial cover with cooling fan, locking chair wheels will be purchased from Amazon as separate items or in "configurable kits"". VRComfort Labs believes the new business model may be the first to utilize Amazon for a complete system integration application.

VRComfort Labs further stated the new VRComfort Vuetm assembly will have all the same functional attributes as the original design. Functionality attributes include eliminating VR motion sickness, uncomfortable head straps, loss of battery power, red "racoon" eye puffiness, facial overheating and other causes of discomfort which result in a negative VR immersion experience. The VRComfort Vuetm stationary boundary platform was designed for and is still targeting primarily adult consumers interested in VR/Metaverse engagement, but not room scale or high interactivity apps such as esports, gaming, or virtual exercising. Instead, the target adult consumers are interested in a multitude of VR/Metaverse stationary boundary, low interactivity apps. Some of the most popular include visiting art galleries, museums, wildlife preserves, archaeological sites, attending auctions, educational classes, theater performances, concerts, sporting events and many other categories.

Media Contact

John Deters, VRComfort Labs, 770-238-2085, [email protected]

SOURCE VRComfort Labs


These press releases may also interest you

at 01:50
SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test
SHL Telemedicine Ltd. ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is proud to announce that it has expanded its offering in Israel to include the groundbreaking ability to perform at-home...

at 01:45
The European Union needs to implement new standards for personal image protection says Robert Szustkowski
His appeal stems from...

at 01:35
KKR Invests in Healthcare Revenue Solutions Provider Infinx
KKR, a leading global investment firm, and Infinx Services Private Limited ("Infinx" or the 'Company'), an AI-driven healthcare revenue cycle solutions provider, today announced the acquisition of a significant minority stake in Infinx by a...

at 01:18
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
. Hansa Biopharma, "Hansa" (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant Congress (ATC), the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American...

at 01:05
Elliptic Labs Shipping AI Virtual Smart Sensor on vivo's Y200 Smartphone
Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensorstm currently deployed in over 500 million devices, is announcing the deployment of its AI Virtual Proximity Sensortm INNER BEAUTY® on vivo's...

at 01:05
FDA Grants Breakthrough Therapy Designation to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with...

More news about Science and technology...


News published on and distributed by: